Population
Patients with stable coronary heart disease, NYHA class I–III chronic heart failure, chronic kidney disease, and type 2 diabetes
Follow-up
a year
Answers are grounded in this paper and cite their sources.
Biomarker dynamics in multimorbid stable CHD may inform remodeling; leaves open whether they predict outcomes or alter therapy.
The article assesses dynamics of the concentration of biomarkers of fibrosis and remodeling in the patients with stable coronary heart disease combined with chronic heart failure I–III functional class according to the NYHA classification, chronic kidney disease and type 2 diabetes against the background of therapy conducted during a year.
No takes yet. Share an insight, caveat, or question.
Belaya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: